Metastatic Lung Cancer
49
14
19
15
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.2%
6 terminated out of 49 trials
71.4%
-15.1% vs benchmark
2%
1 trials in Phase 3/4
33%
5 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 15 completed trials
Clinical Trials (49)
Effects of Infusion Timing on Treatment Response in Solid Tumors
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)
Exercise as Maintenance Therapy in Advanced Lung Cancer
Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients
Description of Neurocognitive and Psychiatric Disorders Associated With Targeted Therapies Used in the Treatment of Lung Cancers With ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway
A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer
A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases
CALM: Managing Distress in Malignant Brain Cancer
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG